CME
Managing Indolent Systemic Mastocytosis: A Multidisciplinary Case Review
April 24, 2024
Host: Cem Akin, MD, PhD Guest: Daniel J. DeAngelo, MD, PhD New tyrosine kinase inhibitor (TKI) treatment options can significantly reduce symptom burden in patients with moderate to severe indolent systemic mastocytosis (ISM). Studies report
Visit Podcast Website
RSS Podcast Feed
Subscribe
Share
Add to MyCast
Gain access to Blubrry tools that help build your podcast, including free podcast stats!